Search

Saul Ewing brought on Peter Murphy as a cannabis industry partner based in the firm’s Wilmington, Delaware, office. He arrives at the firm from cannabis company American Fiber. (Saul Ewing)

Higher Law: Do States' Pro-Labor Cannabis Laws Risk Federal Backlash? | Cannabis Law Partner Joins Saul Ewing | Complaints Renewed About Weedmaps Listings Peter Murphy has joined Saul Ewing as a partner in the firm’s cannabis law practice. He was most recently chief legal officer at American Fiber...

Midyear Cannabis Update: 4 Industry Trends to Watch Saul Ewing’s Jonathan Havens shares the biggest developments he’s seen so far in 2022, as well as which trends industry stakeholders should watch during the second half of the year.

FDA Bans JUUL Products From US Market Cannabis industry stakeholders weigh in on what the decision could mean for businesses in the cannabis space. By Melissa Schiller On the other hand, Jonathan Havens, co-chair of Saul Ewing’s Cannabis Law Practice and chair of the firm’s Food, Beverage and...

FDA takes another look at CBD, but insiders are skeptical much will change U.S. health regulators are taking their closest look in more than three years at the idea of incorporating cannabinoids into dietary supplements. But hopes are dim that Tuesday’s daylong review by the U.S. Food and Drug...

Cannabis Law Partner Zachary Kobrin was featured in a CTFN article discussing the New York State Attorney General’s investigation into the Columbia Care/Cresco Labs merger. While the move by state authorities represents one of the first antitrust investigations of its kind into the cannabis industry...

FDA Warns Four Companies for Selling Unapproved Animal Drugs That Contain CBD The agency said in its warning letters that the drugs, which are intended for use in food-producing animals, violate the Federal Food, Drug, and Cosmetic Act. By Melissa Schiller Jonathan Havens, co-chair of the Cannabis...

AstraZeneca’s ambitious vaccine dreams are finally, officially dead One major caveat: even if the bill passes, it would be up to the FDA to decide when to crack down — and not everyone is convinced they will. “I’m, for one, a bit skeptical that this would immediately change [things] too much, unless...